Aratana Therapeutics, Inc.

If you purchased Aratana Therapeutics, Inc. securities and would like to join the action, please click "Join This Class Action" below.

ARATANA (PETX) MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF ARATANA THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS – PETX

April 26, 2019.

New York, New York—Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the sale of Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (NASDAQ: PETX) to Elanco Animal Health (“Elanco”) is fair to Aratana shareholders.

On April 26, 2019, HC Wainwright set a target price for Aratana at $5.00 per share, or 10% higher than Elanco’s offer valued at $4.75 per share. The investigation concerns whether Aratana and its Board of Directors violated the federal securities laws and/or their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Aratana shareholders; (2) determine whether Elanco is underpaying for Aratana; and (3) disclose all material information necessary for Aratana shareholders to adequately assess and value the merger consideration.

On behalf of Aratana shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLP represent investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Join This Class Action

Scroll to Top